A MULTI-CENTER, OPEN-LABEL, PROOF-OF-CONCEPT STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFECT ON SPUTUM PSEUDOMONAS AERUGINOSA DENSITY OF INHALED LIPOSOMAL CIPROFLOXACIN HYDROCHLORIDE IN ADULT SUBJECTS WITH NON-CF BRONCHIECTASIS.

Trial Profile

A MULTI-CENTER, OPEN-LABEL, PROOF-OF-CONCEPT STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFECT ON SPUTUM PSEUDOMONAS AERUGINOSA DENSITY OF INHALED LIPOSOMAL CIPROFLOXACIN HYDROCHLORIDE IN ADULT SUBJECTS WITH NON-CF BRONCHIECTASIS.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2011

At a glance

  • Drugs Ciprofloxacin (Primary)
  • Indications Pseudomonal infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Nov 2011 Official title amended as reported by European Clinical Trials Database.
    • 21 Oct 2010 Status changed from active, no longer recruiting to completed, as reported in an Aradigm media release.
    • 14 Sep 2009 Results were presented at the ERS Annual Congress 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top